CRBP

Over the past six months, several events impacted CRBP's stock price: In September 2026, positive topline results from the CANYON-1 Phase 1b study for CRB-913 in obesity, showing significant weight loss, led to a rise in the stock price. In July 2026, the U.S. FDA cleared the initiation of the TEMPO-1 registrational study for CRB-701 for Nectin-4 expressing tumors, and Leonardo Viana Nicacio was appointed as Chief Medical Officer. In August 2026, Q2 2026 financial results showed increased operating expenses due to a $10.0 million development milestone payment related to the CRB-701 licensing agreement. Overall, CRBP stock experienced a decline of 16.32% over the past six months, with the share price at $8.08 as of September 14, 2026, a 13.77% decline from the previous year.